AU2013249191B2 - Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation - Google Patents

Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation Download PDF

Info

Publication number
AU2013249191B2
AU2013249191B2 AU2013249191A AU2013249191A AU2013249191B2 AU 2013249191 B2 AU2013249191 B2 AU 2013249191B2 AU 2013249191 A AU2013249191 A AU 2013249191A AU 2013249191 A AU2013249191 A AU 2013249191A AU 2013249191 B2 AU2013249191 B2 AU 2013249191B2
Authority
AU
Australia
Prior art keywords
seq
smad7
antisense oligonucleotide
diabetes
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013249191A
Other languages
English (en)
Other versions
AU2013249191A1 (en
Inventor
Peter Buchwald
Luca Inverardi
Giovanni Monteleone
Antonello Pileggi
Camillo Ricordi
Alice TOMEI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
University of Miami
Original Assignee
Nogra Pharma Ltd
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, University of Miami filed Critical Nogra Pharma Ltd
Publication of AU2013249191A1 publication Critical patent/AU2013249191A1/en
Application granted granted Critical
Publication of AU2013249191B2 publication Critical patent/AU2013249191B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013249191A 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation Ceased AU2013249191B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
US61/625,904 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (2)

Publication Number Publication Date
AU2013249191A1 AU2013249191A1 (en) 2014-10-09
AU2013249191B2 true AU2013249191B2 (en) 2019-01-03

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013249191A Ceased AU2013249191B2 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Country Status (14)

Country Link
US (3) US10081809B2 (cg-RX-API-DMAC7.html)
EP (1) EP2839004B1 (cg-RX-API-DMAC7.html)
JP (2) JP6348484B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150003824A (cg-RX-API-DMAC7.html)
CN (2) CN107252492A (cg-RX-API-DMAC7.html)
AU (1) AU2013249191B2 (cg-RX-API-DMAC7.html)
CA (1) CA2870547A1 (cg-RX-API-DMAC7.html)
DK (1) DK2839004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2732252T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN08158A (cg-RX-API-DMAC7.html)
MX (1) MX370149B (cg-RX-API-DMAC7.html)
NZ (1) NZ630914A (cg-RX-API-DMAC7.html)
RU (1) RU2667960C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013158868A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2704092T3 (es) * 2014-04-30 2019-03-14 Procter & Gamble Composición limpiadora
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
JP7495126B2 (ja) * 2018-05-08 2024-06-04 ユニヴァーシティー オブ マイアミ 組織への治療用核酸の送達のための材料および方法
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037368A2 (en) * 2001-11-02 2003-05-08 Klinikum Der Universität Regensburg Smad7 inhibitors for the treatment of cns diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP3604537B1 (en) 2003-06-13 2021-12-08 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
KR101357016B1 (ko) 2004-09-28 2014-02-03 쿠아크 파마수티칼스 인코퍼레이티드 탈모증, 급성신부전증 및 다른 질환의 치료를 위한올리고리보뉴클레오티드 및 그것의 사용방법
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
WO2009129544A1 (en) * 2008-04-18 2009-10-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
ES2673209T3 (es) 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
EP3693736A3 (en) 2014-10-17 2020-10-14 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CA3014383A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
CA3048334A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037368A2 (en) * 2001-11-02 2003-05-08 Klinikum Der Universität Regensburg Smad7 inhibitors for the treatment of cns diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nora G. Smart et al., "Conditional Expression of Smad7 in Pancreatic-ß Cells Disrupts TGF-ß Signaling and Induces Reversible Diabetes Mellitus", Plos Biology, (2006-02-28), vol. 4, no. 2 *

Also Published As

Publication number Publication date
CN104487574B (zh) 2017-07-07
AU2013249191A1 (en) 2014-10-09
CA2870547A1 (en) 2013-10-24
US10443056B2 (en) 2019-10-15
CN104487574A (zh) 2015-04-01
IN2014DN08158A (cg-RX-API-DMAC7.html) 2015-05-01
EP2839004A1 (en) 2015-02-25
RU2014146170A (ru) 2016-06-10
WO2013158868A1 (en) 2013-10-24
DK2839004T3 (da) 2019-07-01
US20200239884A1 (en) 2020-07-30
EP2839004B1 (en) 2019-06-12
RU2667960C2 (ru) 2018-09-25
MX2014012650A (es) 2015-04-08
NZ630914A (en) 2017-01-27
MX370149B (es) 2019-12-03
US20190136237A1 (en) 2019-05-09
KR20150003824A (ko) 2015-01-09
CN107252492A (zh) 2017-10-17
US10081809B2 (en) 2018-09-25
HK1207117A1 (en) 2016-01-22
JP2015514778A (ja) 2015-05-21
ES2732252T3 (es) 2019-11-21
JP6348484B2 (ja) 2018-06-27
US20150315573A1 (en) 2015-11-05
JP2018131468A (ja) 2018-08-23

Similar Documents

Publication Publication Date Title
US10443056B2 (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
KR101800333B1 (ko) 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
AU2018211325B2 (en) Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
KR20170122769A (ko) 지방이상증 집단에서 아포지단백질 C-III (ApoCIII) 발현의 조절
HK1207117B (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US20210290595A1 (en) Gfi1 inhibitors for the treatment of hyperglycemia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired